Definition
G1 Therapeutics, Inc. is a publicly traded, clinical‑stage biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of cancer, with an emphasis on agents that protect the bone marrow from chemotherapy‑induced damage.
Overview
Headquartered in San Diego, California, United States, G1 Therapeutics focuses on the development of small‑molecule inhibitors targeting the G1 phase of the cell‑cycle, particularly cyclin‑dependent kinases 4 and 6 (CDK4/6). Its lead product, trilaciclib (branded Cosela), is a CDK4/6 inhibitor designed to provide myelopreservation—i.e., to reduce chemotherapy‑induced myelosuppression—when administered prior to standard chemotherapy regimens. In 2021, trilaciclib received U.S. Food and Drug Administration (FDA) approval for use in combination with etoposide and carboplatin in adult patients with extensive‑stage small‑cell lung cancer (SCLC). The company’s pipeline includes additional investigational agents and combination strategies intended to broaden the clinical utility of myelopreservation across multiple tumor types. G1 Therapeutics is listed on the NASDAQ stock exchange under the ticker symbol GTHX.
Etymology/Origin
The name “G1” refers to the G1 phase of the cell‑cycle, a period in which cells grow and prepare for DNA synthesis. By targeting molecular pathways active during this phase, the company aims to intervene in cancer cell proliferation while simultaneously protecting normal hematopoietic cells.
Characteristics
| Characteristic | Description |
|---|---|
| Corporate Structure | Incorporated in the United States; publicly traded (NASDAQ: GTHX). |
| Primary Indication | Myelopreservation in patients receiving myelosuppressive chemotherapy, initially approved for extensive‑stage SCLC. |
| Key Product | Trilaciclib (Cosela) – a short‑acting CDK4/6 inhibitor administered intravenously prior to chemotherapy. |
| Research Focus | Development of CDK4/6‑based therapies, exploration of combination regimens with immuno‑oncology agents, and expansion of myelopreservation indications to additional cancers (e.g., triple‑negative breast cancer, ovarian cancer). |
| Location | Corporate headquarters in San Diego, California; additional research sites and collaborations in the United States and Europe. |
| Regulatory Status | FDA‑approved product (Cosela); several investigational new drug (IND) applications in various phases of clinical development. |
| Financial Highlights | Conducted an initial public offering (IPO) in 2020, raising capital to advance its pipeline. Accurate detailed financial figures are not confirmed. |
| Leadership | The company’s executive leadership team includes a chief executive officer and a board of directors; specific names are not confirmed in publicly verified sources. |
Related Topics
- Cyclin‑Dependent Kinase 4/6 (CDK4/6) Inhibitors – a class of drugs that interfere with cell‑cycle progression, used in various oncology indications.
- Myelopreservation – therapeutic strategies aimed at protecting bone‑marrow function during chemotherapy.
- Small‑Cell Lung Cancer (SCLC) – an aggressive form of lung cancer for which trilaciclib received its first FDA approval.
- Biopharmaceutical Industry – the sector encompassing companies that develop biologically derived drugs and therapeutics.
- NASDAQ Stock Exchange – the electronic securities market where G1 Therapeutics’ shares are listed under the ticker GTHX.
Note: Certain corporate details such as founding date, founder identities, and specific financial metrics are not fully confirmed in publicly available encyclopedic sources.